Effektivnost' i bezopasnost' ezhenedel'nogo vvedeniya paklitaksela bol'nym metastaticheskim rakom molochnoy zhelezy: rezul'taty prospektivnogo mnogotsentrovogo klinicheskogo issledovaniya
- Authors: Stroyakovskiy D.L.1, Makhson A.N.1, Bolotina L.V.1, Gorbunova V.A.1, Koroleva L.A.1, Bagrova S.G.1, Borisova T.A.1, Kornietskaya A.L.1, Ivanov R.A.1, Nikitin K.D.1
-
Affiliations:
- Issue: No 8 (2012)
- Pages: 68-73
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/279566
- ID: 279566
Cite item
Abstract
Keywords
Full Text
About the authors
Daniil L'vovich Stroyakovskiy
Anatoliy Nakhimovich Makhson
Larisa Vladimirovna Bolotina
Vera Andreevna Gorbunova
Lyudmila Alekseevna Koroleva
Svetlana Gennad'evna Bagrova
Tat'yana Anatol'evna Borisova
Anna Leonidovna Kornietskaya
Roman Alekseevich Ivanov
Kirill Dmitrievich Nikitin
References
- Злокачественные новообразования в России в 2010 году (заболеваемость и смертность) / Под ред. В.И. Чиссова, В.В. Старинского, Г.В. Петровой. М., 2012. 260 с. ил.
- Abrams JS, Vena DA, Batz J, et al. Paclitaxel activity in heavily pretreated breast cancer: A National Cancer Institute Treatment Referral Center trial. J Clin Oncol 1995;13: 2056-65.
- Cardoso F, Bedard PL, Winer EP, et al.; ESO-MBC Task Force. International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst 2009;101(17):1174-81.
- Cardoso F, Senkus-Konefka E, Fallowfield L, Costa A, Castiglione M; ESMO Guidelines Working Group. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(5):15-9.
- Nabholtz JM, Gelmon K, Bontenbal M, et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 1996;14:1858-67.
- Pentheroudakis G, Razis E, Athanassiadis A, et al. Paclitaxel-carboplatin combination chemotherapy in advanced breast cancer: accumulating evidence for synergy, efficacy, and safety. Med Oncol 2006;23(2):147-60.
- Perez EA, Suman VJ, Rowland KM, et al. Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer 2005;6(5):425-32.
- Seidman AD, Hudis CA, Albanel J, et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998;16:3353-61.
- Seidman AD, Tiersten A, Hudis C, et al. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 1995;13:2575-81.
- Smith RE, Brown AM, Mamounas EP, et al. Randomized trial of 3-hour versus 2-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26. J Clin Oncol 1999;17:3403-11.
- ten Tije AJ, Smorenburg CH, Seynaeve C, et al. Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicenter phase II trial. Eur J Cancer 2004;40:352-57.
- Wist EA, Sommer HH, Ostenstad B, et al. Weekly one-hour paclitaxel as first-line chemotherapy for metastatic breast cancer. Acta Oncol 2004;3:11-4.